Fig. 7

Combined in vivo effects of MP1 and temsirolimus (TEM) in subcutaneous and orthotopic MYC-MB bearing xenografts. A Tumor volume measurement of subcutaneously xenografted mice (n = 5 each group) following treatments. The differences between treatment groups represent ANOVA-based comparison of the tumor volumes 23 days post-treatment. *p < 0.05; **p < 0.02; ***p < 0.005; ****p < 0.001. B Representative IHC images (40 × magnification with 60 µm scale bar) of MYC and Ki-67 in treated subcutaneous xenografts. C The percentages of MYC and Ki-67 positive cells derived from histology scores were semi-quantified in the subcutaneous tumors of three xenografted mice following 21 days of treatment with inhibitors. *p < 0.05; **p < 0.01; ***p < 0.001 (ANOVA). D Survival analysis of orthotopic MYC-amplified MB-bearing mice (n = 5 each group) using Kaplan–Meier method. The survival comparisons between treatment groups (Vehicle vs. single agents or single agents vs. combination) were determined using the log-rank test. E Representative H&E images (20 × magnification with 200 µm scale bar) with an arrow bar showing the tumor growth in mouse cerebellum with each treatment. (F) Bar graph shows the quantification of H&E-stained tumor area in the cerebellum of each treatment group (n = 3) using Image-J. Tumor area in the treatment groups was calculated as percentages normalized to the tumor area in the control (vehicle treatment) group. *p < 0.05; **p < 0.01; ***p < 0.001 (ANOVA)